Fiona C Brown
I am an expert in cancer biology, acute myeloid leukaemia (AML) and patient-derived xenograft models. I completed my PhD in red cell biology at the University of Melbourne in 2013. I then undertook a postdoctorate position at Memorial Sloan Kettering Cancer Center in New York, where I investigated mechanisms of resistance to intensive chemotherapy in patients with AML. I returned to Australia in 2017 and joined the laboratory of Prof. Andrew Wei firstly at Monash University (Australian Centre for Blood Diseases) and currently at WEHI since 2023 where I lead a translational research program. My research focus is understanding the evolution of TP53 mutated AML and resistance mechanisms to Venetoclax treatment. I have secured research funding from NHMRC and collaborate widely with industry partners including AstraZeneca, Johnson and Johnson, and Storm Therapeutics to test novel agents for therapeutic potential against AML.
Abstracts this author is presenting: